PharmAla Biotech Holdings Inc., a biotechnology company specializing in the research, development, and manufacturing of MDXX class molecules, has announced a binding sales agreement with Numinus Wellness Inc. The agreement entails providing PharmAla's GMP LaNeo MDMA for a prospective clinical trial, highlighting LaNeo as the preferred drug product for MDMA clinical trials globally and for prescribers alike. With a focus on alleviating the backlog of generic, clinical-grade MDMA for clinical trials and commercial sales, PharmAla aims to advance research in the psychedelics industry while developing novel drugs within the same class.
In addition to its collaboration with Numinus, PharmAla showcased key data at the 16th annual Behaviour, Biology and Chemistry conference, presenting findings from the in-vivo performance of its ABA family of drug candidates. The company's commitment to pioneering research and development in psychedelics is underscored by its completion of proof-of-concept research into several IP families, including its lead drug candidate, ALA-002. PharmAla's status as a "regulatory first" organization reflects its dedication to fostering strong relationships with regulators, recognizing that success in the psychedelics industry hinges on compliance and collaboration with regulatory authorities.
